Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Celgene Corp (CELG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 106,433,576
  • Shares Outstanding, K 780,820
  • Annual Sales, $ 11,229 M
  • Annual Income, $ 1,999 M
  • 36-Month Beta 1.89
  • Price/Sales 9.39
  • Price/Cash Flow 22.42
  • Price/Book 13.79

Price Performance

See More
Period Period Low Period High Performance
1-Month
128.82 +6.92%
on 06/30/17
138.17 -0.31%
on 07/21/17
+4.91 (+3.70%)
since 06/21/17
3-Month
113.63 +21.22%
on 05/31/17
138.17 -0.31%
on 07/21/17
+15.48 (+12.66%)
since 04/21/17
52-Week
96.93 +42.10%
on 10/25/16
138.17 -0.31%
on 07/21/17
+30.29 (+28.19%)
since 07/21/16

Most Recent Stories

More News
Is a Beat in the Cards for Vertex (VRTX) in Q2 Earnings?

Impressive performance of Vertex Pharmaceuticals' (VRTX) cystic fibrosis drugs Kalydeco and Orkambi may drive the stock to an earnings beat in Q2.

CELG : 137.74 (+1.05%)
PTI : 3.51 (-3.70%)
VRTX : 163.17 (+2.41%)
GILD : 73.76 (+0.46%)
HCA Healthcare (HCA) Q2 Earnings: Will it Beat Estimates?

HCA Healthcare's (HCA) second-quarter earnings are likely to witness equivalent, admission growth and accretion from a number of acquisitions. Commercial business will likely be a dampener.

CELG : 137.74 (+1.05%)
HCA : 85.73 (-0.03%)
GILD : 73.76 (+0.46%)
PFE : 33.48 (-0.18%)
Amgen (AMGN) to Report Q2 Earnings: What's in the Cards?

While Amgen, Inc.'s (AMGN) growth drugs like Prolia & Xgeva might continue to do well. Biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.

CELG : 137.74 (+1.05%)
NVS : 84.99 (-0.50%)
GILD : 73.76 (+0.46%)
AMGN : 180.21 (+0.50%)
Celgene Corp Rises 1.31% on Heavy Volume: Watch For Potential Pullback

Celgene Corp (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $134.60 to a high of $136.84. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of...

CELG : 137.74 (+1.05%)
The Zacks Analyst Blog Highlights: Apple, JPMorgan, Celgene, PayPal and Vertex Pharmaceuticals

The Zacks Analyst Blog Highlights: Apple, JPMorgan, Celgene, PayPal and Vertex Pharmaceuticals

PYPL : 58.67 (-0.71%)
AAPL : 150.27 (-0.05%)
CELG : 137.74 (+1.05%)
JPM : 90.89 (-0.34%)
VRTX : 163.17 (+2.41%)
Top Stock Reports for Apple, JPMorgan & Celgene

Top Stock Reports for Apple, JPMorgan & Celgene

PYPL : 58.67 (-0.71%)
CELG : 137.74 (+1.05%)
AAPL : 150.27 (-0.05%)
PNC : 126.24 (-0.56%)
JPM : 90.89 (-0.34%)
VRTX : 163.17 (+2.41%)
J&J (JNJ) Beats on Q2 Earnings, Lags Sales, Ups 2017 View

Johnson & Johnson (JNJ) reported mixed second-quarter 2017 results. While earnings beat expectations, sales missed the same.

CELG : 137.74 (+1.05%)
JNJ : 135.31 (-0.92%)
MRK : 62.63 (-0.49%)
PFE : 33.48 (-0.18%)
5 CAR-T Stocks in Focus as NVS Drug Wins FDA Advisory Panel Vote

It's time to look at these 5 CAR-T stocks given the interest generated by a positive FDA advisory panel vote for Novartis' (NVS) experimental CAR-T treatment.

CELG : 137.74 (+1.05%)
NVS : 84.99 (-0.50%)
ZIOP : 6.10 (unch)
BLCM : 11.83 (+0.25%)
KITE : 109.15 (-0.67%)
NK : 7.13 (-1.25%)
JUNO : 29.69 (+2.24%)
Amgen (AMGN) Gets CRL for Osteoporosis Drug Evenity's BLA

Amgen Inc. (AMGN) and partner UCB SA (UCBJF) announced that the FDA has issued a complete response letter (CRL) for the biologics license application (BLA) for Evenity (romosozumab).

CELG : 137.74 (+1.05%)
MRK : 62.63 (-0.49%)
AMGN : 180.21 (+0.50%)
UCBJF : 69.2000 (+0.79%)
3 ETFs Loaded with Positive ESP Stocks

Betting on ETFs with the winning combination of stocks that have a positive Earnings ESP and a favorable Zacks Rank #1, 2 or 3 would lead to profits in investor portfolios.

ALK : 88.25 (-0.95%)
CELG : 137.74 (+1.05%)
IYT : 170.51 (-0.13%)
LSTR : 87.20 (-0.11%)
BBH : 131.44 (+0.70%)
AAL : 51.91 (-0.82%)
KSU : 105.25 (+1.13%)
DAL : 52.26 (-1.08%)
MCD : 153.92 (-0.19%)
R : 72.48 (+0.04%)
TWX : 99.47 (+0.05%)
PEJ : 41.75 (-0.43%)
UNP : 104.85 (-1.22%)
GILD : 73.76 (+0.46%)
NSC : 117.85 (-0.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.

See More

Support & Resistance

2nd Resistance Point 138.97
1st Resistance Point 137.64
Last Price 137.74
1st Support Level 134.79
2nd Support Level 133.27

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.